ClinicalTrials.gg
CompletedNCT05004350NAUTICALCRCUpdated Apr 30, 2026Results posted

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

A Phase 2 interventional study of Encorafenib and Cetuximab in BRAF V600E and Metastatic Colorectal Cancer, sponsored by Pierre Fabre Medicament. Completed at 34 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing encorafenib in Colorectal Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. encorafenib · Colorectal Neoplasms.

Enrollment
5th of 16
107 · median 95
Started
2021
the only one that year
Phase 2
9 of 16
4 open now
Registered
9th of 16
by date
Lead sponsor
2 of 16
Pierre Fabre Medicament

Among the 16 studies testing encorafenib in Colorectal Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2021, is one of 9 in phase 2, and was the 9th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 16 studies testing encorafenib in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About encorafenib

encorafenib: first FDA approval 2018 (BRAFTOVI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing encorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic colorectal cancer (mCRC), who have received prior systemic therapy.

03

Conditions studied

  • BRAF V600E
  • Metastatic Colorectal Cancer

Keywords

  • BRAF V600E
  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Molecular Prescreening:

The following inclusion criteria must be met for a participant to be eligible to undergo molecular tumor prescreening:

  • Chinese male or female participant with age ≥18 years at the time of .
  • - or cytologically-confirmed colorectal cancer (CRC) that is .
  • Eligible to receive cetuximab per Chinese approved label with regard to tumor Rat Sarcoma Viral Oncogene Homologue (RAS) mutation status (i.e. approved for Rat Sarcoma Viral Oncogene Homologue Wild Type(RAS wt) status).
  • Able to provide a sufficient amount of representative tumor specimen for central prospective laboratory testing of B-RAF Proto-oncogene, Serine/threonine Kinase (BRAF) mutation status and also retrospective RAS wt status and Microsatellite Instability (MSI) testing.

Inclusion Criteria for Treatment Period:

The following inclusion criteria must be met for a participant to be eligible for this study:

  • Chinese male or female participant with age ≥18 years at time of informed consent.
  • Histologically or cytologically confirmed CRC that is metastatic and unresectable at time of study entry (i.e. not suitable for complete surgical resection at screening).
  • Presence of a BRAF V600E mutation in tumor tissue previously determined by a local assay at any time before screening or by the central laboratory.

NOTE: Other protocol defined Inclusion criteria may apply

Exclusion Criteria for Molecular Prescreening:

Participants meeting any of the following criteria are not eligible to undergo molecular tumor prescreening:

  • Prior anti-Epidermal Growth Factor Receptor (anti-EGFR) treatment
  • More than two prior regimens in the metastatic setting.
  • Known to receive cetuximab or irinotecan at the planned dose according to the most recent cetuximab and irinotecan local label.
  • Known history of Gilbert's syndrome or is known to have any of the following genotypes: uridine 5'-diphospho-glucuronosyltransferase (UGT)1A1*6/*6, UGT1A1*28/*28 or UGT1A1*6/*28.
  • .

Exclusion Criteria for Treatment Period:

  • Prior treatment with any Proto oncogene Serine/threonine-Protein Kinase (RAF) inhibitor, cetuximab, panitumumab or other EGFR inhibitors.
  • Symptomatic .
  • Leptomeningeal disease.
  • Use of any herbal medications/supplements or any medications or foods that are moderate or strong inhibitors or inducers of cytochrome P450 (CYP)3A4/5 ≤1 week before the start of study intervention.
  • Known history of acute or chronic pancreatitis within 6 months before the start of study intervention.

NOTE: Other protocol defined Exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Encorafenib and cetuximab

    Safety Lead-in (SLI) phase: 28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly Randomized (Phase II) phase: 28 day cycles of encorafenib once daily (QD) 300 mg (4 x 75 mg oral capsule) and cetuximab 400 mg/m² initial dose (120-minute infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly

    Drug: Encorafenib · Drug: Cetuximab

  • Experimental
    Irinotecan and cetuximab or FOLFIRI and cetuximab

    Randomized (Phase II) phase: Either irinotecan and cetuximab or FOLFIRI and cetuximab in 28 day cycles. Irinotecan and cetuximab: * irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks and * cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly OR FOLFIRI and cetuximab: * irinotecan 180 mg/m² (90-minute intravenous infusion or to study site standards) every 2 weeks * Folinic acid 400 mg/m² (120-minute infusion or to study site standards) or maximal dose tolerated in a prior regimen every 2 weeks * 5-FU 400 mg/m² initial dose bolus (not to exceed 15 minutes), then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46 to 48 hours) continuous infusion or maximal dose tolerated in a prior regimen every 2 weeks and * cetuximab 400 mg/m² initial dose (120-minute intravenous infusion), then 250 mg/m² (60-minute infusion) thereafter once weekly

    Drug: Encorafenib · Drug: Cetuximab · Drug: FOLFIRI

Interventions

  • oral hard capsule

    Also known as: Braftovi®, PF-07263896, W0090, LGX818, ONO-7702

  • intravenous infusion

    Also known as: Erbitux®, C225

  • DrugFOLFIRI

    Combination of: irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion

    Also known as: Folinic acid + Fluorouracil + Irinotecan

06

What researchers measure

Primary outcomes

  1. Safety Lead-in Phase (SLI): Incidence of Dose Limiting Toxicities (DLTs)

    DLT rate was estimated based on data from DLT-evaluable participants during the DLT-evaluation period (which is the first 28 days after the first dose of study intervention in the SLI) to assess the safety and tolerability of the doublet arm.

    Time frame: Cycle 1 (up to 28 days)

  2. Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Primary Completion Date

    PFS was defined as the time from the date of randomization to the earliest documented disease progression (PD) as determined by BICR assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause.

    Time frame: From first dose to the earliest documented progression or death due to any cause, with a minimal participant's follow-up of 36 weeks and a maximum treatment exposure of 68 weeks

  3. Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Final Analysis

    PFS was defined as the time from the date of randomization to the earliest documented disease progression as determined by BICR assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause.

    Time frame: From first dose to the earliest documented PD or death due to any cause, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks

Secondary outcomes

  1. Safety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per BICR

    cORR as determined by Blinded (to treatment received) Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 111 weeks

  2. Safety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per Investigator

    cORR as determined by investigator assessment per RECIST version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 111 weeks

  3. Safety Lead-in Phase: Duration of Response (DOR) Per BICR

    DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by BICR per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.

    Time frame: From time of response to the earliest documented PD or death due to underlying disease, with a maximum treatment exposure of 111 weeks

  4. Safety Lead-in Phase: Duration of Response (DOR) Per Investigator

    DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.

    Time frame: From time of response to the earliest documented PD or death due to underlying disease, with a maximum treatment exposure of 111 weeks

  5. Safety Lead-in Phase: Overall Duration of Exposure to Study Treatment

    Exposure to the study intervention was defined as the time interval between the actual date of first study intervention administration (included) and the actual date of last study intervention administration (included), i.e., as the quantity "date of last study intervention administration date of first study intervention administration + 1 day". Duration of exposure by treatment arm was computed as the maximum of all durations of exposure for each drug of the assigned regimen.

    Time frame: Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 111 weeks

  6. Safety Lead-in Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE is any untoward medical occurrence in a participant temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting TEAEs were reported in this outcome measure.

    Time frame: Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 111 weeks

  7. Safety Lead-in Phase: Number of Participants With Serious TEAEs

    A serious TEAE is a TEAE that results in significant health consequences, such as death, hospitalization, or permanent disability. Number of participants reporting serious TEAEs were reported in this outcome measure.

    Time frame: Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 111 weeks

  8. Safety Lead-in Phase: Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant, whether or not considered related to the study intervention. Number of participants with dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure.

    Time frame: Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 68 weeks

  9. Safety Lead-in Phase: Number of Participants With Clinically Notable Vital Sign Abnormalities

    Clinically notable changes were defined as participants meeting the elevated or low values criterion compared to baseline. The criterion for clinically notable elevated values included: systolic blood pressure (BP): ≥ 160 millimeters of mercury (mmHg) and an increase ≥ 20 mmHg from baseline; diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; heart rate : ≥ 120 beats/min (bpm) with increase from baseline of ≥ 15 bpm; weight (kg) increase from baseline of ≥ 10 percent; body temperature \[degree Celsius (deg C)\] ≥ 37.5 deg C. The criterion for clinically notable low values included: systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; heart rate: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; weight: ≥ 20 percent decrease from baseline; body temperature \[deg C\]: ≤ 36 °C.

    Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks

  10. Safety Lead-in Phase: Number of Participants With Clinically Notable Electrocardiogram (ECG) Values

    Clinically notable ECG changes were defined as participants meeting the criterion for QT interval, QT interval corrected for heart rate using Fridericia's formula (QTcF), and heart rate compared to baseline. The criterion for QT interval and QTcF included: increase from baseline \> 30 msec (ms); increase from baseline \> 60 ms, new \> 450 ms, new \> 480 ms, new \> 500 ms. The criterion for heart rate included: increase from baseline \> 25 percent to a value \> 100 beats per minute (bpm), decrease from baseline \> 25 percent and to a value \< 50 bpm.

    Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks

  11. Safety Lead-in Phase: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters

    Clinically notable shift was defined as a worsening from baseline by at least 2 Grades, or to Grade 3 or above based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.

    Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks

  12. Safety Lead-in Phase: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters

    Clinically notable shift was defined as a worsening from baseline by at least 2 Grades, or to Grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.

    Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks

  13. Safety Lead-in Phase: Number of Participants With Notable Dermatological Abnormalities

    Dermatological examination was performed to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and primary melanoma, as these have been reported to occur with selective B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor treatment. \[1\] The category "Other" includes all other dermatological findings identified during examination (e.g. rash acneiform, skin hyperpigmentation...).

    Time frame: From screening and every 8 weeks from Cycle 1 Day 1 (i.e. on Day 1 of Cycles 1, 3, 5, 7…), the end of treatment visit and the 30-day safety follow up visit, with a maximum treatment exposure of 111 weeks

  14. Safety Lead-in Phase: Measurement of Performance Status Using the Eastern Co-operative Oncology Group (ECOG) Scale

    The performance status of participants was assessed using the Eastern Co-operative Oncology Group (ECOG) scale. The scale was defined with the range from 0 to 5 with lower score mean a lower functional impairment, and a higher score (e.g. 5) corresponding to death.

    Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 68 weeks

  15. Safety Lead-in Phase: Evaluation of the Plasma Concentrations of Encorafenib

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

    Time frame: First day of treatment (Cycle 1 Day I) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  16. Safety Lead-in Phase: Evaluation of the Serum Concentrations of Cetuximab

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  17. Safety Lead-in Phase: Evaluation of the Area Under the Curve (AUC) Derived From Plasma Concentration of Encorafenib

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  18. Safety Lead-in Phase: Evaluation of the Area Under the Curve (AUC) Derived From Serum Concentration of Cetuximab

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  19. Safety Lead-in Phase: Evaluation of the Maximum Concentration (Cmax) Derived From Plasma Concentration of Encorafenib

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  20. Safety Lead-in Phase: Evaluation of the Maximum Concentration (Cmax) Derived From Serum Concentration of Cetuximab

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  21. Safety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Plasma Concentration of Encorafenib

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  22. Safety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Serum Concentration of Cetuximab

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  23. Randomized Phase 2: Progression-free Survival (PFS) by Investigator

    PFS was defined as the time from the date of randomization to the earliest documented date of PD as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.

    Time frame: From first dose to the earliest documented PD or death due to any cause, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks

  24. Randomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per BICR

    cORR as determined by Blinded (to treatment received) Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks

  25. Randomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per Investigator

    cORR as determined by investigator assessment per RECIST Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks

  26. Randomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per BICR

    DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by BICR per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.

    Time frame: From time of response to the earliest documented PD or death due to underlying disease, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks

  27. Randomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per Investigator

    DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.

    Time frame: From time of response to the earliest documented PD or death due to underlying disease, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks

  28. Randomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per BICR

    cDCR was defined as the proportion of participants with a confirmed Best Overall Response (BOR) of CR, PR or Stable Disease (SD), as determined by BICR per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks

  29. Randomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per Investigator

    cDCR was defined as the proportion of participants with a confirmed Best Overall Response (BOR) of CR, PR or Stable Disease (SD), as determined by investigator assesment per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks

  30. Randomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per BICR

    TTR for confirmed responses was defined for responders (CR or PR) as the time between the date of randomization until the first documented response of CR or PR as determined by BICR per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From day 1 until first documented response, with a maximum treatment exposure of 116 weeks

  31. Randomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per Investigator

    TTR for confirmed responses was defined for responders (CR or PR) as the time between the date of randomization until the first documented response of CR or PR as determined by investigator assessment per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From day 1 until first documented response, with a maximum treatment exposure of 116 weeks

  32. Randomized Phase 2: Overall Survival (OS)

    OS was defined as time from randomization until date of death due to any cause.

    Time frame: From randomization to death due to any cause, with a maximum treatment exposure of 116 weeks

  33. Randomized Phase 2: Overall Duration of Exposure to Study Treatment

    Exposure to the study intervention was defined as the time interval between the actual date of first study intervention administration (included) and the actual date of last study intervention administration (included), i.e., as the quantity "date of last study intervention administration date of first study intervention administration + 1 day". Duration of exposure by treatment arm was computed as the maximum of all durations of exposure for each drug of the assigned regimen.

    Time frame: Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 116 weeks

  34. Randomized Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE is any untoward medical occurrence in a participant temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting TEAEs were reported in this outcome measure.

    Time frame: Day 1 until 30 days after study intervention discontinuation

  35. Randomized Phase 2: Number of Participants With Serious TEAEs

    A serious TEAE is a TEAE that results in significant health consequences, such as death, hospitalization, or permanent disability. Number of participants reporting serious TEAEs were reported in this outcome measure.

    Time frame: Day 1 until 30 days after study intervention discontinuation

  36. Randomized Phase 2: Number of Participants With Clinically Notable Vital Sign Abnormalities

    Clinically notable changes were defined as participants meeting the elevated or low values criterion compared to baseline. The criterion for clinically notable elevated values included: systolic blood pressure (BP): ≥ 160 millimeters of mercury (mmHg) and an increase ≥ 20 mmHg from baseline; diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; heart rate : ≥ 120 beats/min (bpm) with increase from baseline of ≥ 15 bpm; weight (kg) increase from baseline of ≥ 10 percent; body temperature \[degree Celsius (deg C)\] ≥ 37.5 deg C. The criterion for clinically notable low values included: systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; heart rate: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; weight: ≥ 20 percent decrease from baseline; body temperature \[deg C\]: ≤ 36 °C.

    Time frame: Day 1 until 30 days after last dose of study treatment

  37. Randomized Phase 2: Number of Participants With Clinically Notable Electrocardiogram (ECG) Values

    Clinically notable ECG changes were defined as participants meeting the criterion for QT interval, QT interval corrected for heart rate using Fridericia's formula (QTcF), and heart rate compared to baseline. The criterion for QT interval and QTcF included: increase from baseline \> 30 msec (ms); increase from baseline \> 60 ms, new \> 450 ms, new \> 480 ms, new \> 500 ms. The criterion for heart rate included: increase from baseline \> 25 percent to a value \> 100 beats per minute (bpm), decrease from baseline \> 25 percent and to a value \< 50 bpm.

    Time frame: Day 1 until 30 days after last dose of study treatment

  38. Randomized Phase 2: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters

    Clinically notable shift was defined as a worsening from baseline by at least 2 grades, or to grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.

    Time frame: Day 1 until 30 days after last dose of study treatment

  39. Randomized Phase 2: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters

    Clinically notable shift was defined as a worsening from baseline by at least 2 grades, or to grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.

    Time frame: Day 1 until 30 days after last dose of study treatment

  40. Randomized Phase 2: Number of Participants With Notable Dermatological Abnormalities

    Dermatological examination was performed to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and primary melanoma, as these have been reported to occur with selective B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor treatment. \[1\] All other dermatological findings identified during examination (e.g. rash acneiform, skin hyperpigmentation...).

    Time frame: From screening and every 8 weeks from Cycle 1 Day 1 (i.e. on Day 1 of Cycles 1, 3, 5, 7…), the end of treatment visit and the 30-day safety follow up visit, with a maximum treatment exposure of 116 weeks

  41. Randomized Phase 2: Measurement of Performance Status Using the Eastern Co-operative Oncology Group (ECOG) Scale

    The performance status of participants was assessed using the Eastern Co-operative Oncology Group (ECOG) scale. The scale was defined with the range from 0 to 5 with lower score mean a lower functional impairment, and a higher score (e.g. 5) corresponding to death. \[1\] Participants with no assessment of ECOG in the time frame.

    Time frame: Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 116 weeks

  42. Randomized Phase 2: Time to Definitive Deterioration in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) Questionnaire Scores

    The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) questionnaire consisted of nine multi-item scales: five functional scales (physical, role, cognitive, emotional and social); three symptom scales (fatigue, pain, nausea and vomiting); and a global health and Quality of Life (QoL) scale. Each scale in the questionnaire was scored (0 to 100). High scores represented a high health/quality of life. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.

    Time frame: Day 1 until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks

  43. Randomized Phase 2: Time to Definitive Deterioration in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire

    The European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) consisted of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system consisted of five dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each was rated according to a five-point verbal rating scale (VRS): 1. no problems, 2. slight problems, 3. moderate problems, 4. severe problems and 5. extreme problems) and translated into a five-digit number that described the participant's health state. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.

    Time frame: Day 1 until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks

  44. Randomized Phase 2: Time to Definitive Deterioration in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) Questionnaire

    The Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) was a validated quality of life questionnaire for patient reported outcome assessment. The Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) consisted of 36 items, presented on a five-point Likert scale, in four domains of well-being (physical, emotional, social and functional) and the Colorectal Cancer Subscale. Higher score reflects a better quality of life. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.

    Time frame: Day 1 until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks

  45. Randomized Phase 2: Evolution in the Patient Global Impression of Change (PGIC) Questionnaire

    The Patient Global Impression of Change (PGIC) questionnaire is a scale often used to anchor and characterize participant reported outcome (PRO) findings. This consisted of questions that asked participants to evaluate their colorectal cancer symptoms since starting study intervention according to a seven-point verbal rating scale: 1. very much improved, 2. much improved, 3. minimally improved, 4. no change, 5. minimally worse, 6. much worse, 7. very much worse. Completions of questionnaire are summarized per treatment group and study visits. Number of participants analyzed correspond to the actual number of participants who completed the questionnaire at the corresponding visit.

    Time frame: Cycle 2 Day 1 until 30 days safety follow-up

  46. Randomized Phase 2: Evaluation of the Plasma Concentrations of Encorafenib

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  47. Randomized Phase 2: Evaluation of the Serum Concentrations of Cetuximab

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  48. Randomized Phase 2: Evaluation of the Area Under the Curve (AUC) Derived From Plasma Concentration of Encorafenib

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  49. Randomized Phase 2: Evaluation of the Area Under the Curve (AUC) Derived From Serum Concentration of Cetuximab

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  50. Randomized Phase 2: Evaluation of the Minimum Concentration (Cmin) Derived From Plasma Concentration of Encorafenib

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  51. Randomized Phase 2: Evaluation of the Minimum Concentration (Cmin) Derived From Serum Concentration of Cetuximab

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  52. Randomized Phase 2: Evaluation of the Maximum Concentration (Cmax) Derived From Plasma Concentration of Encorafenib

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

  53. Randomized Phase 2: Evaluation of the Maximum Concentration (Cmax) Derived From Serum Concentration of Cetuximab

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

    Time frame: First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.

07

Results

Posted Apr 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneSafety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Started106532
Completed020
Not completed106332
Withdrew: Adverse event165
Withdrew: Progressive disease95617
Withdrew: Withdrawal by subject019
Withdrew: Non-compliance with study drug001

Outcome measures

PrimarySafety Lead-in Phase (SLI): Incidence of Dose Limiting Toxicities (DLTs)

DLT rate was estimated based on data from DLT-evaluable participants during the DLT-evaluation period (which is the first 28 days after the first dose of study intervention in the SLI) to assess the safety and tolerability of the doublet arm.

Time frame:
Cycle 1 (up to 28 days)
Reported as:
Count of participants · Participants
Safety Lead-in Phase (SLI): Incidence of Dose Limiting Toxicities (DLTs)
ParticipantsSafety Lead-in Phase: ENCO + CETUX
Safety Lead-in Phase (SLI): Incidence of Dose Limiting Toxicities (DLTs)0
PrimaryRandomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Primary Completion Date

PFS was defined as the time from the date of randomization to the earliest documented disease progression (PD) as determined by BICR assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause.

Time frame:
From first dose to the earliest documented progression or death due to any cause, with a minimal participant's follow-up of 36 weeks and a maximum treatment exposure of 68 weeks
Reported as:
Median · months
Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Primary Completion Date
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Primary Completion Date4.2 (3.0 to 7.3)2.5 (1.3 to 4.3)
Statistical analysis
  • Randomized Phase: ENCO + CETUX vs Randomized Phase: Control Arm · Stratified Log-rank · p = 0.0004 · Stratified hazard ratio: 0.37 · 95% CI 0.20 to 0.68
PrimaryRandomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Final Analysis

PFS was defined as the time from the date of randomization to the earliest documented disease progression as determined by BICR assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause.

Time frame:
From first dose to the earliest documented PD or death due to any cause, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks
Reported as:
Median · months
Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Final Analysis
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to Treatment Received) Independent Central Review (BICR) at the Final Analysis4.2 (3.0 to 6.9)2.5 (1.3 to 4.3)
Statistical analysis
  • Randomized Phase: ENCO + CETUX vs Randomized Phase: Control Arm · Stratified Log-rank · p = 0.0004 · Stratified hazard ratio: 0.37 · 95% CI 0.20 to 0.68
SecondarySafety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per BICR

cORR as determined by Blinded (to treatment received) Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 111 weeks
Reported as:
Number · percentage of participants
Safety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per BICR
percentage of participantsSafety Lead-in Phase (SLI): ENCO + CETUX
Safety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per BICR30 (6.7 to 65.2)
SecondarySafety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per Investigator

cORR as determined by investigator assessment per RECIST version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 111 weeks
Reported as:
Number · percentage of participants
Safety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per Investigator
percentage of participantsSafety Lead-in Phase (SLI): ENCO + CETUX
Safety Lead-in Phase: Confirmed Objective Response Rate (cORR) Per Investigator30 (6.7 to 65.2)
SecondarySafety Lead-in Phase: Duration of Response (DOR) Per BICR

DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by BICR per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.

Time frame:
From time of response to the earliest documented PD or death due to underlying disease, with a maximum treatment exposure of 111 weeks
Reported as:
Median · months
Safety Lead-in Phase: Duration of Response (DOR) Per BICR
monthsSafety Lead-in Phase (SLI): ENCO + CETUX
Safety Lead-in Phase: Duration of Response (DOR) Per BICR12.5 (3.6 to NA)
SecondarySafety Lead-in Phase: Duration of Response (DOR) Per Investigator

DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.

Time frame:
From time of response to the earliest documented PD or death due to underlying disease, with a maximum treatment exposure of 111 weeks
Reported as:
Median · months
Safety Lead-in Phase: Duration of Response (DOR) Per Investigator
monthsSafety Lead-in Phase (SLI): ENCO + CETUX
Safety Lead-in Phase: Duration of Response (DOR) Per Investigator7 (4.2 to NA)
SecondarySafety Lead-in Phase: Overall Duration of Exposure to Study Treatment

Exposure to the study intervention was defined as the time interval between the actual date of first study intervention administration (included) and the actual date of last study intervention administration (included), i.e., as the quantity "date of last study intervention administration date of first study intervention administration + 1 day". Duration of exposure by treatment arm was computed as the maximum of all durations of exposure for each drug of the assigned regimen.

Time frame:
Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 111 weeks
Reported as:
Median · weeks
Safety Lead-in Phase: Overall Duration of Exposure to Study Treatment
weeksSafety Lead-in Phase: ENCO + CETUX
Safety Lead-in Phase: Overall Duration of Exposure to Study Treatment16.50 (4.0 to 110.9)
SecondarySafety Lead-in Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE is any untoward medical occurrence in a participant temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting TEAEs were reported in this outcome measure.

Time frame:
Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 111 weeks
Reported as:
Count of participants · Participants
Safety Lead-in Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsSafety Lead-in Phase: ENCO + CETUX
Safety Lead-in Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs)10
SecondarySafety Lead-in Phase: Number of Participants With Serious TEAEs

A serious TEAE is a TEAE that results in significant health consequences, such as death, hospitalization, or permanent disability. Number of participants reporting serious TEAEs were reported in this outcome measure.

Time frame:
Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 111 weeks
Reported as:
Count of participants · Participants
Safety Lead-in Phase: Number of Participants With Serious TEAEs
ParticipantsSafety Lead-in Phase: ENCO + CETUX
Safety Lead-in Phase: Number of Participants With Serious TEAEs1
SecondarySafety Lead-in Phase: Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant, whether or not considered related to the study intervention. Number of participants with dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure.

Time frame:
Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 68 weeks
Reported as:
Count of participants · Participants
Safety Lead-in Phase: Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)
ParticipantsSafety Lead-in Phase (SLI): ENCO + CETUX
Dose interruptions3
Dose modifications3
Discontinuations due to AEs1
SecondarySafety Lead-in Phase: Number of Participants With Clinically Notable Vital Sign Abnormalities

Clinically notable changes were defined as participants meeting the elevated or low values criterion compared to baseline. The criterion for clinically notable elevated values included: systolic blood pressure (BP): ≥ 160 millimeters of mercury (mmHg) and an increase ≥ 20 mmHg from baseline; diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; heart rate : ≥ 120 beats/min (bpm) with increase from baseline of ≥ 15 bpm; weight (kg) increase from baseline of ≥ 10 percent; body temperature \[degree Celsius (deg C)\] ≥ 37.5 deg C. The criterion for clinically notable low values included: systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; heart rate: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; weight: ≥ 20 percent decrease from baseline; body temperature \[deg C\]: ≤ 36 °C.

Time frame:
Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks
Reported as:
Count of participants · Participants
Safety Lead-in Phase: Number of Participants With Clinically Notable Vital Sign Abnormalities
ParticipantsSafety Lead-in Phase: ENCO + CETUX
Systolic BP: >= 160 mmHg and an increase >= 20 mmHg from baseline1
Diastolic BP: >= 100 mmHg and an increase >= 15 mmHg from baseline0
Heart rate: >= 120 bpm with increase from baseline of >=15 bpm1
Weight: increase from baseline of >= 10%0
Body temperature [deg C]: >= 37.5 deg C2
SecondarySafety Lead-in Phase: Number of Participants With Clinically Notable Electrocardiogram (ECG) Values

Clinically notable ECG changes were defined as participants meeting the criterion for QT interval, QT interval corrected for heart rate using Fridericia's formula (QTcF), and heart rate compared to baseline. The criterion for QT interval and QTcF included: increase from baseline \> 30 msec (ms); increase from baseline \> 60 ms, new \> 450 ms, new \> 480 ms, new \> 500 ms. The criterion for heart rate included: increase from baseline \> 25 percent to a value \> 100 beats per minute (bpm), decrease from baseline \> 25 percent and to a value \< 50 bpm.

Time frame:
Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks
Reported as:
Count of participants · Participants
Safety Lead-in Phase: Number of Participants With Clinically Notable Electrocardiogram (ECG) Values
ParticipantsSafety Lead-in Phase: ENCO + CETUX
QT Interval - Increase from baseline > 30 ms4
QT Interval - Increase from baseline > 60 ms0
QT interval - New > 450 ms0
QT interval - New > 480 ms0
QT interval - New > 500 ms0
QTcF Interval - Increase from baseline > 30 ms4
QTcF Interval - Increase from baseline > 60 ms1
QTcF Interval - New > 450 ms1
QTcF Interval - New > 480 ms1
QTcF Interval - New > 500 ms0
Heart rate - Increase from baseline > 25% to a value > 100 bpm2
Heart rate - Decrease from baseline > 25% and to a value < 50 bpm0
SecondarySafety Lead-in Phase: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters

Clinically notable shift was defined as a worsening from baseline by at least 2 Grades, or to Grade 3 or above based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.

Time frame:
Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks
Reported as:
Count of participants · Participants
Safety Lead-in Phase: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters
ParticipantsSafety Lead-in Phase (SLI): ENCO + CETUX
Hemoglobin (g/L) (Low)2
Hemoglobin (g/L) (High)0
Leukocytes (10/L) (Low)0
Leukocytes (10/L) (High)0
Neutrophils (10/L) (Low)0
Platelets (10/L) (Low)0
Lymphocytes (10/L) (Low)1
Lymphocytes (10/L) (High)0
SecondarySafety Lead-in Phase: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters

Clinically notable shift was defined as a worsening from baseline by at least 2 Grades, or to Grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.

Time frame:
Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 111 weeks
Reported as:
Count of participants · Participants
Safety Lead-in Phase: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters
ParticipantsSafety Lead-in Phase (SLI): ENCO + CETUX
Alanine Aminotransferase (IU/L) (High)0
Albumin (g/L) (Low)0
Alkaline Phosphatase (IU/L) (High)0
Amylase (IU/L) (High)0
Aspartate Aminotransferase (IU/L) (High)0
Bilirubin (micromol/L) (High)0
Calcium Corrected (mmol/L) (Low)1
Calcium Corrected (mmol/L) (High)0
Creatinine (umol/L) (High)1
Creatine Kinase (IU/L) (High)0
Glucose, Fasting (mmol/L) (Low)0
Glucose, Fasting (mmol/L) (High)1
Lipase (IU/L) (High)0
Magnesium (mmol/L) (Low)0
Magnesium (mmol/L) (High)0
Potassium (mmol/L) (Low)0
Potassium (mmol/L) (High)0
Sodium (mmol/L) (Low)0
Sodium (mmol/L) (High)0
Troponin I (ug/L) (High)0
Troponin T (ug/L) (High)0
Urate (umol/L) (High)0
SecondarySafety Lead-in Phase: Number of Participants With Notable Dermatological Abnormalities

Dermatological examination was performed to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and primary melanoma, as these have been reported to occur with selective B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor treatment. \[1\] The category "Other" includes all other dermatological findings identified during examination (e.g. rash acneiform, skin hyperpigmentation...).

Time frame:
From screening and every 8 weeks from Cycle 1 Day 1 (i.e. on Day 1 of Cycles 1, 3, 5, 7…), the end of treatment visit and the 30-day safety follow up visit, with a maximum treatment exposure of 111 weeks
Reported as:
Count of participants · Participants
Safety Lead-in Phase: Number of Participants With Notable Dermatological Abnormalities
ParticipantsSafety Lead-in Phase (SLI): ENCO + CETUX
Keratoacanthoma1
Squamous Cell Carcinoma0
Primary Melanoma0
Other [1]8
SecondarySafety Lead-in Phase: Measurement of Performance Status Using the Eastern Co-operative Oncology Group (ECOG) Scale

The performance status of participants was assessed using the Eastern Co-operative Oncology Group (ECOG) scale. The scale was defined with the range from 0 to 5 with lower score mean a lower functional impairment, and a higher score (e.g. 5) corresponding to death.

Time frame:
Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 68 weeks
Reported as:
Count of participants · Participants
Safety Lead-in Phase: Measurement of Performance Status Using the Eastern Co-operative Oncology Group (ECOG) Scale
ParticipantsSafety Lead-in Phase (SLI): ENCO + CETUX
01
19
SecondarySafety Lead-in Phase: Evaluation of the Plasma Concentrations of Encorafenib

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

Time frame:
First day of treatment (Cycle 1 Day I) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Safety Lead-in Phase: Evaluation of the Plasma Concentrations of Encorafenib
nanogram/milliliter (ng/mL)Safety Lead-in Phase (SLI): ENCO + CETUX
Cycle 1 Day 1 (pre-dose)NA ± NA
Cycle 1 Day 1 (1 hour post-dose)1730 ± 113.2
Cycle 1 Day 1 (2 hours post-dose)4120 ± 63.9
Cycle 1 Day 1 (4 hours post-dose)4290 ± 28.2
Cycle 1 Day 1 (6 hours post-dose)1970 ± 55.6
Cycle 2 Day 1 (pre-dose)11.4 ± 104
Cycle 2 Day 1 (1 hour post-dose)2720 ± 76.7
Cycle 2 Day 1 (2 hours post-dose)2440 ± 42.8
Cycle 2 Day 1 (4 hours post-dose)1070 ± 51.5
Cycle 2 Day 1 (6 hours post-dose)512 ± 67.3
SecondarySafety Lead-in Phase: Evaluation of the Serum Concentrations of Cetuximab

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Safety Lead-in Phase: Evaluation of the Serum Concentrations of Cetuximab
ng/mLSafety Lead-in Phase (SLI): ENCO + CETUX
Cycle 1 Day 1 (pre-dose)NA ± NA
Cycle 1 Day 1 (1 hour post-dose)71800 ± 34.9
Cycle 1 Day 1 (2 hours post-dose)161000 ± 40.6
Cycle 1 Day 1 (4 hours post-dose)240000 ± 13.2
Cycle 1 Day 1 (6 hours post-dose)220000 ± 14.1
Cycle 2 Day 1 (pre-dose)47400 ± 25.2
Cycle 2 Day 1 (1 hour post-dose)144000 ± 19.8
Cycle 2 Day 1 (2 hours post-dose)198000 ± 15.6
Cycle 2 Day 1 (4 hours post-dose)185000 ± 15.4
Cycle 2 Day 1 (6 hours post-dose)199000 ± 7.7
SecondarySafety Lead-in Phase: Evaluation of the Area Under the Curve (AUC) Derived From Plasma Concentration of Encorafenib

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · hour*nanogram/milliliter (h*ng/mL)
Safety Lead-in Phase: Evaluation of the Area Under the Curve (AUC) Derived From Plasma Concentration of Encorafenib
hour*nanogram/milliliter (h*ng/mL)Safety Lead-in Phase (SLI): ENCO + CETUX
Cycle 1 Day 1 (AUC0-6)18200 ± 35.9
Cycle 1 Day 1 (AUC0-tlast)18600 ± 34.9
Cycle 2 Day 1 (AUC0-6)9760 ± 31.4
Cycle 2 Day 1 (AUCtau)12500 ± 34.6
Cycle 2 Day 1 (AUC0-tlast)9870 ± 30.8
SecondarySafety Lead-in Phase: Evaluation of the Area Under the Curve (AUC) Derived From Serum Concentration of Cetuximab

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · h*ng/mL
Safety Lead-in Phase: Evaluation of the Area Under the Curve (AUC) Derived From Serum Concentration of Cetuximab
h*ng/mLSafety Lead-in Phase (SLI): ENCO + CETUX
Cycle 1 Day 1 (AUC0-6)988000 ± 19
Cycle 1 Day 1 (AUC0-tlast)1000000 ± 21.5
Cycle 2 Day 1 (AUC0-6)987000 ± 13.1
Cycle 2 Day 1 (AUC0-tlast)989000 ± 13.1
SecondarySafety Lead-in Phase: Evaluation of the Maximum Concentration (Cmax) Derived From Plasma Concentration of Encorafenib

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Safety Lead-in Phase: Evaluation of the Maximum Concentration (Cmax) Derived From Plasma Concentration of Encorafenib
ng/mLSafety Lead-in Phase (SLI): ENCO + CETUX
Cycle 1 Day 15430 ± 33.7
Cycle 2 Day 14210 ± 41.7
SecondarySafety Lead-in Phase: Evaluation of the Maximum Concentration (Cmax) Derived From Serum Concentration of Cetuximab

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Safety Lead-in Phase: Evaluation of the Maximum Concentration (Cmax) Derived From Serum Concentration of Cetuximab
ng/mLSafety Lead-in Phase (SLI): ENCO + CETUX
Cycle 1 Day 1244000 ± 11.1
Cycle 2 Day 1209000 ± 9.3
SecondarySafety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Plasma Concentration of Encorafenib

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Safety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Plasma Concentration of Encorafenib
ng/mLSafety Lead-in Phase (SLI): ENCO + CETUX
Safety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Plasma Concentration of Encorafenib11.4 ± 104
SecondarySafety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Serum Concentration of Cetuximab

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Safety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Serum Concentration of Cetuximab
ng/mLSafety Lead-in Phase (SLI): ENCO + CETUX
Safety Lead-in Phase: Evaluation of the Minimum Concentration (Cmin) Derived From Serum Concentration of Cetuximab47400 ± 25.2
SecondaryRandomized Phase 2: Progression-free Survival (PFS) by Investigator

PFS was defined as the time from the date of randomization to the earliest documented date of PD as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.

Time frame:
From first dose to the earliest documented PD or death due to any cause, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks
Reported as:
Median · months
Randomized Phase 2: Progression-free Survival (PFS) by Investigator
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Progression-free Survival (PFS) by Investigator4.2 (4.0 to 5.5)2.5 (1.3 to 3.9)
Statistical analysis
  • Randomized Phase: ENCO + CETUX vs Randomized Phase: Control Arm · Stratified Log-rank · p = <0.0001 · Stratified hazard ratio: 0.29 · 95% CI 0.16 to 0.50
SecondaryRandomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per BICR

cORR as determined by Blinded (to treatment received) Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Reported as:
Number · percentage of participants
Randomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per BICR
percentage of participantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per BICR23.1 (13.5 to 35.2)6.3 (0.8 to 20.8)
SecondaryRandomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per Investigator

cORR as determined by investigator assessment per RECIST Version 1.1, was defined as the proportion of participants with a best overall response of either complete response (CR) or partial response (PR), where CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Reported as:
Number · percentage of participants
Randomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per Investigator
percentage of participantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Confirmed Objective Response Rate (cORR) in ENCO + CETUX Arm vs Control Arm Per Investigator27.7 (17.3 to 40.2)6.3 (0.8 to 20.8)
SecondaryRandomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per BICR

DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by BICR per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.

Time frame:
From time of response to the earliest documented PD or death due to underlying disease, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks
Reported as:
Median · months
Randomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per BICR
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per BICR5.6 (2.8 to 18.0)NA (NA to NA)
SecondaryRandomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per Investigator

DOR was defined for confirmed responders (CR or PR) only, as the time from the date of the first documented response to the earliest date of disease progression (PD) as determined by investigator assessment per RECIST Version 1.1, or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated.

Time frame:
From time of response to the earliest documented PD or death due to underlying disease, with a minimal participant's follow-up of 19 months and a maximum treatment exposure of 116 weeks
Reported as:
Median · months
Randomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per Investigator
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Duration of Response (DOR) in ENCO + CETUX Arm vs Control Arm Per Investigator4.0 (2.8 to 6.9)NA (NA to NA)
SecondaryRandomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per BICR

cDCR was defined as the proportion of participants with a confirmed Best Overall Response (BOR) of CR, PR or Stable Disease (SD), as determined by BICR per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Reported as:
Number · percentage of participants
Randomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per BICR
percentage of participantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per BICR75.4 (63.1 to 85.2)28.1 (13.7 to 46.7)
SecondaryRandomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per Investigator

cDCR was defined as the proportion of participants with a confirmed Best Overall Response (BOR) of CR, PR or Stable Disease (SD), as determined by investigator assesment per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Every 6 weeks (± 7 days) from first dose for the first 24 week, then every 12 weeks (± 7 days) until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Reported as:
Number · percentage of participants
Randomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per Investigator
percentage of participantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Confirmed Disease Control Rate (cDCR) in ENCO + CETUX Arm vs Control Arm Per Investigator78.5 (66.5 to 87.7)37.5 (21.1 to 56.3)
SecondaryRandomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per BICR

TTR for confirmed responses was defined for responders (CR or PR) as the time between the date of randomization until the first documented response of CR or PR as determined by BICR per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From day 1 until first documented response, with a maximum treatment exposure of 116 weeks
Reported as:
Median · months
Randomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per BICR
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per BICR1.4 (1.3 to 1.6)1.5 (1.4 to NA)
SecondaryRandomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per Investigator

TTR for confirmed responses was defined for responders (CR or PR) as the time between the date of randomization until the first documented response of CR or PR as determined by investigator assessment per RECIST Version 1.1. CR: disappearance of all target and and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From day 1 until first documented response, with a maximum treatment exposure of 116 weeks
Reported as:
Median · months
Randomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per Investigator
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Time to Response (TTR) in ENCO + CETUX Arm vs Control Arm Per Investigator1.5 (1.3 to 2.7)1.6 (1.4 to NA)
SecondaryRandomized Phase 2: Overall Survival (OS)

OS was defined as time from randomization until date of death due to any cause.

Time frame:
From randomization to death due to any cause, with a maximum treatment exposure of 116 weeks
Reported as:
Median · months
Randomized Phase 2: Overall Survival (OS)
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Overall Survival (OS)11.9 (8.2 to 16.6)8.2 (5.2 to 12.4)
Statistical analysis
  • Randomized Phase: ENCO + CETUX vs Randomized Phase: Control Arm · Stratified Log-rank · p = 0.0075 · Stratified hazard ratio: 0.54 · 95% CI 0.32 to 0.89
SecondaryRandomized Phase 2: Overall Duration of Exposure to Study Treatment

Exposure to the study intervention was defined as the time interval between the actual date of first study intervention administration (included) and the actual date of last study intervention administration (included), i.e., as the quantity "date of last study intervention administration date of first study intervention administration + 1 day". Duration of exposure by treatment arm was computed as the maximum of all durations of exposure for each drug of the assigned regimen.

Time frame:
Day 1 until 30 days after study intervention discontinuation, with a maximum treatment exposure of 116 weeks
Reported as:
Median · weeks
Randomized Phase 2: Overall Duration of Exposure to Study Treatment
weeksRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Overall Duration of Exposure to Study Treatment18.90 (1.0 to 116.3)8.00 (2.0 to 22.6)
SecondaryRandomized Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE is any untoward medical occurrence in a participant temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting TEAEs were reported in this outcome measure.

Time frame:
Day 1 until 30 days after study intervention discontinuation
Reported as:
Count of participants · Participants
Randomized Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs)6527
SecondaryRandomized Phase 2: Number of Participants With Serious TEAEs

A serious TEAE is a TEAE that results in significant health consequences, such as death, hospitalization, or permanent disability. Number of participants reporting serious TEAEs were reported in this outcome measure.

Time frame:
Day 1 until 30 days after study intervention discontinuation
Reported as:
Count of participants · Participants
Randomized Phase 2: Number of Participants With Serious TEAEs
ParticipantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Number of Participants With Serious TEAEs205
SecondaryRandomized Phase 2: Number of Participants With Clinically Notable Vital Sign Abnormalities

Clinically notable changes were defined as participants meeting the elevated or low values criterion compared to baseline. The criterion for clinically notable elevated values included: systolic blood pressure (BP): ≥ 160 millimeters of mercury (mmHg) and an increase ≥ 20 mmHg from baseline; diastolic BP: ≥ 100 mmHg and an increase ≥ 15 mmHg from baseline; heart rate : ≥ 120 beats/min (bpm) with increase from baseline of ≥ 15 bpm; weight (kg) increase from baseline of ≥ 10 percent; body temperature \[degree Celsius (deg C)\] ≥ 37.5 deg C. The criterion for clinically notable low values included: systolic BP: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg; diastolic BP: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg; heart rate: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm; weight: ≥ 20 percent decrease from baseline; body temperature \[deg C\]: ≤ 36 °C.

Time frame:
Day 1 until 30 days after last dose of study treatment
Reported as:
Count of participants · Participants
Randomized Phase 2: Number of Participants With Clinically Notable Vital Sign Abnormalities
ParticipantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Systolic BP: >= 160 mmHg and an increase >= 20 mmHg from baseline20
Diastolic BP: >= 100 mmHg and an increase >= 15 mmHg from baseline10
Heart rate: >= 120 bpm with increase from baseline of >=15 bpm21
Weight: increase from baseline of >= 10%61
Body temperature [deg C]: >= 37.5 deg C71
Systolic BP: <= 90 mmHg with decrease from baseline of >= 20 mmHg70
Diastolic BP: <= 50 mmHg with decrease from baseline of >= 15 mmHg30
Heart rate: <= 50 bpm with decrease from baseline of >= 15 bpm10
Weight: >= 20% decrease from baseline00
Body temperature [deg C]: <= 36 deg C327
SecondaryRandomized Phase 2: Number of Participants With Clinically Notable Electrocardiogram (ECG) Values

Clinically notable ECG changes were defined as participants meeting the criterion for QT interval, QT interval corrected for heart rate using Fridericia's formula (QTcF), and heart rate compared to baseline. The criterion for QT interval and QTcF included: increase from baseline \> 30 msec (ms); increase from baseline \> 60 ms, new \> 450 ms, new \> 480 ms, new \> 500 ms. The criterion for heart rate included: increase from baseline \> 25 percent to a value \> 100 beats per minute (bpm), decrease from baseline \> 25 percent and to a value \< 50 bpm.

Time frame:
Day 1 until 30 days after last dose of study treatment
Reported as:
Count of participants · Participants
Randomized Phase 2: Number of Participants With Clinically Notable Electrocardiogram (ECG) Values
ParticipantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
QT Interval - Increase from baseline > 30 ms372
QT Interval - Increase from baseline > 60 ms71
QT interval - New > 450 ms21
QT interval - New > 480 ms10
QT interval - New > 500 ms00
QTcF Interval - Increase from baseline > 30 ms241
QTcF Interval - Increase from baseline > 60 ms21
QTcF Interval - New > 450 ms92
QTcF Interval - New > 480 ms01
QTcF Interval - New > 500 ms01
Heart rate - Increase from baseline > 25% to a value > 100 bpm109
Heart rate - Decrease from baseline > 25% and to a value < 50 bpm10
SecondaryRandomized Phase 2: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters

Clinically notable shift was defined as a worsening from baseline by at least 2 grades, or to grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.

Time frame:
Day 1 until 30 days after last dose of study treatment
Reported as:
Count of participants · Participants
Randomized Phase 2: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters
ParticipantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Hemoglobin (g/L) (Low)77
Hemoglobin (g/L) (High)00
Leukocytes (10/L) (Low)213
Leukocytes (10/L) (High)00
Neutrophils (10/L) (Low)411
Platelets (10/L) (Low)30
Lymphocytes (10/L) (Low)118
Lymphocytes (10/L) (High)11
SecondaryRandomized Phase 2: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters

Clinically notable shift was defined as a worsening from baseline by at least 2 grades, or to grade 3 or above based on NCI-CTCAE version 4.03. 'Low' laboratory parameter thresholds are defined as values falling below the institutional Lower Limit of Normal (LLN) that meet the criteria for a Grade 1 or a higher decrease. 'High' laboratory parameter thresholds are defined as values exceeding the institutional Upper Limit of Normal (ULN) that meet the criteria for a Grade 1 or higher increase. Where, Grade 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated; Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death.

Time frame:
Day 1 until 30 days after last dose of study treatment
Reported as:
Count of participants · Participants
Randomized Phase 2: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters
ParticipantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Alanine Aminotransferase (IU/L) (High)30
Albumin (g/L) (Low)31
Alkaline Phosphatase (IU/L) (High)30
Amylase (IU/L) (High)11
Aspartate Aminotransferase (IU/L) (High)20
Bilirubin (micromol/L) (High)21
Calcium Corrected (mmol/L) (Low)20
Calcium Corrected (mmol/L) (High)10
Creatinine (umol/L) (High)63
Creatine Kinase (IU/L) (High)01
Glucose, Fasting (mmol/L) (Low)10
Glucose, Fasting (mmol/L) (High)60
Lipase (IU/L) (High)72
Magnesium (mmol/L) (Low)40
Magnesium (mmol/L) (High)10
Potassium (mmol/L) (Low)00
Potassium (mmol/L) (High)40
Sodium (mmol/L) (Low)53
Sodium (mmol/L) (High)00
Troponin I (ug/L) (High)00
Troponin T (ug/L) (High)00
Urate (umol/L) (High)20
SecondaryRandomized Phase 2: Number of Participants With Notable Dermatological Abnormalities

Dermatological examination was performed to monitor for the possible development of keratoacanthoma and/or squamous cell carcinoma and primary melanoma, as these have been reported to occur with selective B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor treatment. \[1\] All other dermatological findings identified during examination (e.g. rash acneiform, skin hyperpigmentation...).

Time frame:
From screening and every 8 weeks from Cycle 1 Day 1 (i.e. on Day 1 of Cycles 1, 3, 5, 7…), the end of treatment visit and the 30-day safety follow up visit, with a maximum treatment exposure of 116 weeks
Reported as:
Count of participants · Participants
Randomized Phase 2: Number of Participants With Notable Dermatological Abnormalities
ParticipantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Keratoacanthoma00
Squamous Cell Carcinoma00
Primary Melanoma00
Other [1]390
SecondaryRandomized Phase 2: Measurement of Performance Status Using the Eastern Co-operative Oncology Group (ECOG) Scale

The performance status of participants was assessed using the Eastern Co-operative Oncology Group (ECOG) scale. The scale was defined with the range from 0 to 5 with lower score mean a lower functional impairment, and a higher score (e.g. 5) corresponding to death. \[1\] Participants with no assessment of ECOG in the time frame.

Time frame:
Day 1 until 30 days after last dose of study treatment, with a maximum treatment exposure of 116 weeks
Reported as:
Count of participants · Participants
Randomized Phase 2: Measurement of Performance Status Using the Eastern Co-operative Oncology Group (ECOG) Scale
ParticipantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
0175
14615
201
NA [1]26
SecondaryRandomized Phase 2: Time to Definitive Deterioration in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) Questionnaire Scores

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) questionnaire consisted of nine multi-item scales: five functional scales (physical, role, cognitive, emotional and social); three symptom scales (fatigue, pain, nausea and vomiting); and a global health and Quality of Life (QoL) scale. Each scale in the questionnaire was scored (0 to 100). High scores represented a high health/quality of life. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.

Time frame:
Day 1 until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Reported as:
Median · months
Randomized Phase 2: Time to Definitive Deterioration in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) Questionnaire Scores
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Time to Definitive Deterioration in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30) Questionnaire ScoresNA (7.3 to NA)2.5 (1.6 to NA)
SecondaryRandomized Phase 2: Time to Definitive Deterioration in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire

The European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) consisted of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system consisted of five dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each was rated according to a five-point verbal rating scale (VRS): 1. no problems, 2. slight problems, 3. moderate problems, 4. severe problems and 5. extreme problems) and translated into a five-digit number that described the participant's health state. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.

Time frame:
Day 1 until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Reported as:
Median · months
Randomized Phase 2: Time to Definitive Deterioration in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Time to Definitive Deterioration in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire8.0 (5.6 to NA)4.2 (1.6 to 5.9)
SecondaryRandomized Phase 2: Time to Definitive Deterioration in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) Questionnaire

The Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) was a validated quality of life questionnaire for patient reported outcome assessment. The Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) consisted of 36 items, presented on a five-point Likert scale, in four domains of well-being (physical, emotional, social and functional) and the Colorectal Cancer Subscale. Higher score reflects a better quality of life. Time to definitive deterioration (at least 10% worsening relative to Baseline with no later improvement) was assessed for both randomized phase treatment arms.

Time frame:
Day 1 until 30 days safety follow-up, with a maximum treatment exposure of 116 weeks
Reported as:
Median · months
Randomized Phase 2: Time to Definitive Deterioration in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) Questionnaire
monthsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Randomized Phase 2: Time to Definitive Deterioration in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) Questionnaire22.1 (6.0 to NA)2.5 (1.4 to 5.9)
SecondaryRandomized Phase 2: Evolution in the Patient Global Impression of Change (PGIC) Questionnaire

The Patient Global Impression of Change (PGIC) questionnaire is a scale often used to anchor and characterize participant reported outcome (PRO) findings. This consisted of questions that asked participants to evaluate their colorectal cancer symptoms since starting study intervention according to a seven-point verbal rating scale: 1. very much improved, 2. much improved, 3. minimally improved, 4. no change, 5. minimally worse, 6. much worse, 7. very much worse. Completions of questionnaire are summarized per treatment group and study visits. Number of participants analyzed correspond to the actual number of participants who completed the questionnaire at the corresponding visit.

Time frame:
Cycle 2 Day 1 until 30 days safety follow-up
Reported as:
Count of participants · Participants
Randomized Phase 2: Evolution in the Patient Global Impression of Change (PGIC) Questionnaire
ParticipantsRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Cycle 2 Day 1 — Very much improved70
Cycle 2 Day 1 — Much improved293
Cycle 2 Day 1 — Minimally improved159
Cycle 2 Day 1 — No change95
Cycle 2 Day 1 — Minimally worse10
Cycle 2 Day 1 — Much worse00
Cycle 3 Day 1 — Very much improved140
Cycle 3 Day 1 — Much improved223
Cycle 3 Day 1 — Minimally improved124
Cycle 3 Day 1 — No change33
Cycle 3 Day 1 — Minimally worse20
Cycle 3 Day 1 — Much worse01
Cycle 4 Day 1 — Very much improved110
Cycle 4 Day 1 — Much improved232
Cycle 4 Day 1 — Minimally improved52
Cycle 4 Day 1 — No change42
Cycle 4 Day 1 — Minimally worse00
Cycle 4 Day 1 — Much worse00
Cycle 5 Day 1 — Very much improved110
Cycle 5 Day 1 — Much improved141
Cycle 5 Day 1 — Minimally improved40
Cycle 5 Day 1 — No change41
Cycle 5 Day 1 — Minimally worse00
Cycle 5 Day 1 — Much worse00
Cycle 6 Day 1 — Very much improved90
Cycle 6 Day 1 — Much improved101
Cycle 6 Day 1 — Minimally improved40
Cycle 6 Day 1 — No change20
Cycle 6 Day 1 — Minimally worse00
Cycle 6 Day 1 — Much worse00
Cycle 7 Day 1 — Very much improved70
Cycle 7 Day 1 — Much improved70
Cycle 7 Day 1 — Minimally improved20
Cycle 7 Day 1 — No change10
Cycle 7 Day 1 — Minimally worse00
Cycle 7 Day 1 — Much worse00
Cycle 8 Day 1 — Very much improved90
Cycle 8 Day 1 — Much improved50
Cycle 8 Day 1 — Minimally improved20
Cycle 8 Day 1 — No change10
Cycle 8 Day 1 — Minimally worse00
Cycle 8 Day 1 — Much worse00
Cycle 9 Day 1 — Very much improved90
Cycle 9 Day 1 — Much improved40
Cycle 9 Day 1 — Minimally improved10
Cycle 9 Day 1 — No change00
Cycle 9 Day 1 — Minimally worse00
Cycle 9 Day 1 — Much worse00
Cycle 10 Day 1 — Very much improved40
Cycle 10 Day 1 — Much improved60
Cycle 10 Day 1 — Minimally improved20
Cycle 10 Day 1 — No change10
Cycle 10 Day 1 — Minimally worse00
Cycle 10 Day 1 — Much worse00
Cycle 11 Day 1 — Very much improved30
Cycle 11 Day 1 — Much improved80
Cycle 11 Day 1 — Minimally improved00
Cycle 11 Day 1 — No change20
Cycle 11 Day 1 — Minimally worse00
Cycle 11 Day 1 — Much worse00
Cycle 12 Day 1 — Very much improved50
Cycle 12 Day 1 — Much improved60
Cycle 12 Day 1 — Minimally improved00
Cycle 12 Day 1 — No change20
Cycle 12 Day 1 — Minimally worse00
Cycle 12 Day 1 — Much worse00
Cycle 13 Day 1 — Very much improved30
Cycle 13 Day 1 — Much improved40
Cycle 13 Day 1 — Minimally improved10
Cycle 13 Day 1 — No change00
Cycle 13 Day 1 — Minimally worse00
Cycle 13 Day 1 — Much worse00
Cycle 14 Day 1 — Very much improved10
Cycle 14 Day 1 — Much improved40
Cycle 14 Day 1 — Minimally improved10
Cycle 14 Day 1 — No change00
Cycle 14 Day 1 — Minimally worse00
Cycle 14 Day 1 — Much worse00
Cycle 15 Day 1 — Very much improved10
Cycle 15 Day 1 — Much improved40
Cycle 15 Day 1 — Minimally improved00
Cycle 15 Day 1 — No change10
Cycle 15 Day 1 — Minimally worse00
Cycle 15 Day 1 — Much worse00
Cycle 16 Day 1 — Very much improved20
Cycle 16 Day 1 — Much improved20
Cycle 16 Day 1 — Minimally improved10
Cycle 16 Day 1 — No change00
Cycle 16 Day 1 — Minimally worse00
Cycle 16 Day 1 — Much worse00
Cycle 17 Day 1 — Very much improved20
Cycle 17 Day 1 — Much improved20
Cycle 17 Day 1 — Minimally improved00
Cycle 17 Day 1 — No change10
Cycle 17 Day 1 — Minimally worse00
Cycle 17 Day 1 — Much worse00
Cycle 18 Day 1 — Very much improved10
Cycle 18 Day 1 — Much improved30
Cycle 18 Day 1 — Minimally improved10
Cycle 18 Day 1 — No change00
Cycle 18 Day 1 — Minimally worse00
Cycle 18 Day 1 — Much worse00
Cycle 19 Day 1 — Very much improved20
Cycle 19 Day 1 — Much improved30
Cycle 19 Day 1 — Minimally improved00
Cycle 19 Day 1 — No change00
Cycle 19 Day 1 — Minimally worse00
Cycle 19 Day 1 — Much worse00
Cycle 20 Day 1 — Very much improved10
Cycle 20 Day 1 — Much improved30
Cycle 20 Day 1 — Minimally improved10
Cycle 20 Day 1 — No change00
Cycle 20 Day 1 — Minimally worse00
Cycle 20 Day 1 — Much worse00
Cycle 21 Day 1 — Very much improved00
Cycle 21 Day 1 — Much improved40
Cycle 21 Day 1 — Minimally improved10
Cycle 21 Day 1 — No change00
Cycle 21 Day 1 — Minimally worse00
Cycle 21 Day 1 — Much worse00
Cycle 22 Day 1 — Very much improved20
Cycle 22 Day 1 — Much improved10
Cycle 22 Day 1 — Minimally improved10
Cycle 22 Day 1 — No change00
Cycle 22 Day 1 — Minimally worse00
Cycle 22 Day 1 — Much worse00
Cycle 23 Day 1 — Very much improved00
Cycle 23 Day 1 — Much improved30
Cycle 23 Day 1 — Minimally improved00
Cycle 23 Day 1 — No change00
Cycle 23 Day 1 — Minimally worse00
Cycle 23 Day 1 — Much worse00
Cycle 24 Day 1 — Very much improved10
Cycle 24 Day 1 — Much improved20
Cycle 24 Day 1 — Minimally improved00
Cycle 24 Day 1 — No change00
Cycle 24 Day 1 — Minimally worse00
Cycle 24 Day 1 — Much worse00
Cycle 25 Day 1 — Very much improved00
Cycle 25 Day 1 — Much improved10
Cycle 25 Day 1 — Minimally improved00
Cycle 25 Day 1 — No change00
Cycle 25 Day 1 — Minimally worse00
Cycle 25 Day 1 — Much worse00
Cycle 26 Day 1 — Very much improved00
Cycle 26 Day 1 — Much improved10
Cycle 26 Day 1 — Minimally improved00
Cycle 26 Day 1 — No change00
Cycle 26 Day 1 — Minimally worse00
Cycle 26 Day 1 — Much worse00
Cycle 27 Day 1 — Very much improved10
Cycle 27 Day 1 — Much improved00
Cycle 27 Day 1 — Minimally improved00
Cycle 27 Day 1 — No change00
Cycle 27 Day 1 — Minimally worse00
Cycle 27 Day 1 — Much worse00
Cycle 28 Day 1 — Very much improved00
Cycle 28 Day 1 — Much improved10
Cycle 28 Day 1 — Minimally improved00
Cycle 28 Day 1 — No change00
Cycle 28 Day 1 — Minimally worse00
Cycle 28 Day 1 — Much worse00
End of Treatment — Very much improved100
End of Treatment — Much improved153
End of Treatment — Minimally improved117
End of Treatment — No change72
End of Treatment — Minimally worse31
End of Treatment — Much worse31
Safety Follow-up — Very much improved30
Safety Follow-up — Much improved71
Safety Follow-up — Minimally improved31
Safety Follow-up — No change21
Safety Follow-up — Minimally worse10
Safety Follow-up — Much worse02
SecondaryRandomized Phase 2: Evaluation of the Plasma Concentrations of Encorafenib

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Randomized Phase 2: Evaluation of the Plasma Concentrations of Encorafenib
ng/mLRandomized Phase: ENCO + CETUX
Cycle 1 Day 1 (pre-dose)NA ± NA
Cycle 1 Day 1 (1 hour post-dose)2490 ± 242.8
Cycle 1 Day 1 (2 hours post-dose)3850 ± 108.5
Cycle 1 Day 1 (4 hours post-dose)3330 ± 59.4
Cycle 1 Day 1 (6 hours post-dose)2180 ± 70.1
Cycle 2 Day 1 (pre-dose)NA ± NA
Cycle 2 Day 1 (1 hour post-dose)1290 ± 224.3
Cycle 2 Day 1 (2 hours post-dose)2490 ± 41.7
Cycle 2 Day 1 (4 hours post-dose)976 ± 35.4
Cycle 2 Day 1 (6 hours post-dose)461 ± 42.3
SecondaryRandomized Phase 2: Evaluation of the Serum Concentrations of Cetuximab

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Randomized Phase 2: Evaluation of the Serum Concentrations of Cetuximab
ng/mLRandomized Phase: ENCO + CETUX
Cycle 1 Day 1 (pre-dose)NA ± NA
Cycle 1 Day 1 (1 hour post-dose)82500 ± 27.2
Cycle 1 Day 1 (2 hours post-dose)175000 ± 22.7
Cycle 1 Day 1 (4 hours post-dose)222000 ± 30.9
Cycle 1 Day 1 (6 hours post-dose)207000 ± 25.4
Cycle 2 Day 1 (pre-dose)53000 ± 40.6
Cycle 2 Day 1 (1 hour post-dose)170000 ± 28.4
Cycle 2 Day 1 (2 hours post-dose)192000 ± 26.9
Cycle 2 Day 1 (4 hours post-dose)195000 ± 21.1
Cycle 2 Day 1 (6 hours post-dose)184000 ± 26.5
SecondaryRandomized Phase 2: Evaluation of the Area Under the Curve (AUC) Derived From Plasma Concentration of Encorafenib

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · h*ng/mL
Randomized Phase 2: Evaluation of the Area Under the Curve (AUC) Derived From Plasma Concentration of Encorafenib
h*ng/mLRandomized Phase: ENCO + CETUX
Cycle 1 Day 1 (AUC0-6)18400 ± 55.7
Cycle 1 Day 1 (AUC0-tlast)18800 ± 54.7
Cycle 2 Day 1 (AUC0-6)8670 ± 15
Cycle 2 Day 1 (AUCtau)10800 ± 14.3
Cycle 2 Day 1 (AUC0-tlast)8710 ± 14.7
SecondaryRandomized Phase 2: Evaluation of the Area Under the Curve (AUC) Derived From Serum Concentration of Cetuximab

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · hour*nanogram/milliliter
Randomized Phase 2: Evaluation of the Area Under the Curve (AUC) Derived From Serum Concentration of Cetuximab
hour*nanogram/milliliterRandomized Phase: ENCO + CETUX
Cycle 1 Day 1 (AUC0-6)927000 ± 21.5
Cycle 1 Day 1 (AUC0-tlast)927000 ± 21.5
Cycle 2 Day 1 (AUC0-6)994000 ± 26.4
Cycle 2 Day 1 (AUC0-tlast)990000 ± 26.8
SecondaryRandomized Phase 2: Evaluation of the Minimum Concentration (Cmin) Derived From Plasma Concentration of Encorafenib

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Randomized Phase 2: Evaluation of the Minimum Concentration (Cmin) Derived From Plasma Concentration of Encorafenib
ng/mLRandomized Phase: ENCO + CETUX
Cycle 1 Day 1NA ± NA
Cycle 2 Day 17.75 ± 96.1
SecondaryRandomized Phase 2: Evaluation of the Minimum Concentration (Cmin) Derived From Serum Concentration of Cetuximab

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Randomized Phase 2: Evaluation of the Minimum Concentration (Cmin) Derived From Serum Concentration of Cetuximab
ng/mLRandomized Phase: ENCO + CETUX
Cycle 1 Day 1NA ± NA
Cycle 2 Day 153000 ± 40.6
SecondaryRandomized Phase 2: Evaluation of the Maximum Concentration (Cmax) Derived From Plasma Concentration of Encorafenib

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of encorafenib.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Randomized Phase 2: Evaluation of the Maximum Concentration (Cmax) Derived From Plasma Concentration of Encorafenib
ng/mLRandomized Phase: ENCO + CETUX
Cycle 1 Day 15610 ± 48.7
Cycle 2 Day 13700 ± 27.9
SecondaryRandomized Phase 2: Evaluation of the Maximum Concentration (Cmax) Derived From Serum Concentration of Cetuximab

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of cetuximab.

Time frame:
First day of treatment (Cycle 1 Day 1) and at steady state after 1 month treatment (Cycle 2 Day 1). Each cycle of 28 days.
Reported as:
Geometric mean · ng/mL
Randomized Phase 2: Evaluation of the Maximum Concentration (Cmax) Derived From Serum Concentration of Cetuximab
ng/mLRandomized Phase: ENCO + CETUX
Cycle 1 Day 1230000 ± 28.1
Cycle 2 Day 1197000 ± 27.5

Adverse events

Collected over Adverse Events (AE) were collected from when the participant first provided informed consent until 30 days after study intervention discontinuation. For SLI: ENCO + CETUX: maximum treatment exposure of 111 weeks; for Randomized Phase: ENCO + CETUX and Randomized Phase: Control Arm: maximum treatment exposure of 116 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Lead-in Phase: ENCO + CETUX9/10 (90%)1/10 (10%)9/10 (90%)
Randomized Phase: ENCO + CETUX44/65 (67.7%)20/65 (30.8%)45/65 (69.2%)
Randomized Phase: Control Arm24/32 (75%)5/32 (15.6%)22/32 (68.8%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventSafety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
Cerebral infarctionNervous system disorders1/101/650/32
Intestinal obstructionGastrointestinal disorders0/106/652/32
Gastrointestinal perforationGastrointestinal disorders0/100/652/32
Abdominal painGastrointestinal disorders0/100/651/32
DiarrhoeaGastrointestinal disorders0/100/651/32
Gastrointestinal infectionInfections and infestations0/100/651/32
Pneumonia aspirationInfections and infestations0/100/651/32
Septic shockInfections and infestations0/100/651/32
Pericardial effusionCardiac disorders0/102/650/32
PneumoniaInfections and infestations0/102/650/32
Most frequent other events
Showing 10 of 95
Most frequent other events
EventSafety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control Arm
MalaiseGeneral disorders7/109/652/32
Dermatitis acneiformSkin and subcutaneous tissue disorders5/1010/654/32
Decreased appetiteMetabolism and nutrition disorders5/1011/656/32
HyperglycaemiaMetabolism and nutrition disorders5/108/650/32
ArthralgiaMusculoskeletal and connective tissue disorders5/109/651/32
AnaemiaBlood and lymphatic system disorders5/1021/6510/32
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/1014/650/32
White blood cell count decreasedInvestigations0/105/6513/32
Weight decreasedInvestigations4/1016/655/32
DiarrhoeaGastrointestinal disorders4/1010/659/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)Safety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control ArmTotal
Mean57.90 ± 13.1553.52 ± 14.0054.56 ± 14.7854.04 ± 13.74
Age, Customized
Age, Customized(Participants)Safety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control ArmTotal
Age Group — <656491974
Age Group — 65-744101327
Age Group — >= 750606
Sex: Female, Male
Sex: Female, Male(Participants)Safety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control ArmTotal
Female3312155
Male7341152
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control ArmTotal
American Indian or Alaska Native0000
Asian106532107
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Safety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control ArmTotal
China106532107
Body Mass Index
Body Mass Index(kg/m^2)Safety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control ArmTotal
Mean24.19 ± 3.2822.90 ± 3.4722.61 ± 3.2922.93 ± 3.40
Eastern Cooperative Oncology Group Performance Status Case Report Form at Baseline
Eastern Cooperative Oncology Group Performance Status Case Report Form at Baseline(Participants)Safety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control ArmTotal
0722938
13432369
Number of Participants According to Primary Site of Cancer
Number of Participants According to Primary Site of Cancer(Participants)Safety Lead-in Phase: ENCO + CETUXRandomized Phase: ENCO + CETUXRandomized Phase: Control ArmTotal
Colon, Left5391660
Colon, Right5261647

3 further baseline measures are reported on the registry.

08

Study locations

34 sites
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100036, China
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100730, China
  • Fujian Medical University - Fujian Provincial Cancer Hospital
    Fuzhou, Fujian 350014, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361001, China
  • The First People's Hospital of Foshan
    Foshan, Guangdong 528010, China
  • Cancer Center of Guangzhou Medical University
    Guangzhou, Guangdong 510095, China
  • The Sixth Affiliated Hospital Sun Yat-Sen University
    Guangzhou, Guangdong 510655, China
  • Cancer Hospital Affiliated to Shantou University Medical College
    Shantou, Guangdong 515041, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • The Affiliated Hospital of Hebei University
    Baoding, Hebei 071000, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150040, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Union Hospital Tongji medical college Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430071, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • The First People's Hospital of Changzhou
    Changzhou, Jiangsu 213003, China
  • First Affiliated Hospital of Gannan Medical University
    Ganzhou, Jiangxi 341001, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The First Affiliated Hospital of Jinzhou Medical University
    Jinzhou, Liaoning 121011, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110042, China
  • Shaanxi Provincial People's Hospital
    Xi'an, Shaanxi 710068, China
  • Zhongshan Hospital Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • Huashan Hospital Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Xinhua Hospital Affilliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200092, China
  • Shanghai East Hospital, Tongji University
    Shanghai, Shanghai Municipality 200120, China
  • The Second People's Hospital of Neijiang
    Neijiang, Sichuan 641000, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
  • The First Affiliated Hospital - Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Sir Run Run Shaw Hospital - Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
09

References and documents

Publications

  • Xicheng W, Yanhong D, Yanqiao Z, Tianshu L, Xianglin Y, Jianwei Y, Tao Z, Aimin Z, Yu L, Li H, Feng Y, Hong Z, Yi B, Isabelle K, Jean-Claude V, Melanie G, Angela G, Jian L, Lin S. A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study. Cancer Med. 2026 Mar;15(3):e71697. doi: 10.1002/cam4.71697. PubMed 41852303 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Dec 2023, 27 months.

Results were first posted in Apr 2026, 2 years 4 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 27 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2021
First posted
Aug 13, 2021
StartActual
Sep 14, 2021
Primary completionActual
Dec 19, 2023
CompletionActual
Dec 7, 2024
Results first posted
Apr 30, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05004350
Responsible party
Sponsor
First posted
Aug 13, 2021
Start date
Sep 14, 2021
Primary completion
Dec 19, 2023
Completion
Dec 7, 2024
Results posted
Apr 30, 2026
Last update
Apr 30, 2026

Study contacts

Shen Lin, MD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Encorafenib · Cetuximab

Start the discussion